Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be healthy based on by medical history, laboratory work, and physical exam~* Be at least 18 years of age to 65 years of age~* If childbearing potential, use of acceptable form of birth control~* In the case of females of childbearing potential, have a negative serum pregnancy test~Exclusion Criteria:~* Use of a prescription medication within 14 days or over-the-counter products within 7 days prior to administration of study medication~* Known hypersensitivity or allergy to any of the components of the lidocaine topical system formulation~* Any serious illness in the 4 weeks preceding the beginning of treatment that resulted in missed work or hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Lidocaine Patch (Sequence AB) (Type: EXPERIMENTAL): Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
- Lidocaine Patch (Sequence BA) (Type: EXPERIMENTAL): Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).